The influence of treatment with somatostatin analogues on morphology, proliferative and apoptotic activity in GH-secreting pituitary adenomas

J Clin Neurosci. 2003 Jul;10(4):444-8. doi: 10.1016/s0967-5868(03)00072-9.

Abstract

With the aim to investigate histopathological changes and proliferative and apoptotic activity in GH-secreting adenomas we compared 14 cases pre-treated with somatostatin analogues before surgery with a reference group of 17 un-pretreated ones. Besides routine histology, immunocytochemical detection of all pituitary hormones, caspase-3, cytokeratin-18, and "M30 antigen", its apoptosis-specific fragment was performed. Proliferation activity of the tumour was determined by the Ki-67 antigen expression. In treated adenomas more prominent regressive changes were found accompanied by compensatory increase in perivascular fibrosis. The Ki-67 labelling index was lower in treated group (mean 2.5, median 1.6 per mille) than in untreated patients (mean 9.4, median 5.0 per mille). The difference was statistically significant (p=0.049 using Mann-Whitney Rank Sum Test). Apoptosis was detected in only 2 of the 14 pre-treated adenomas, and it was more frequent (9/17) and more prominent in the untreated group.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenoma / diagnostic imaging
  • Adenoma / drug therapy*
  • Adenoma / metabolism
  • Adenoma / pathology
  • Adenoma / surgery
  • Adult
  • Aged
  • Apoptosis
  • Cell Division
  • Combined Modality Therapy
  • Female
  • Fibrosis
  • Human Growth Hormone / metabolism*
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • Pituitary Neoplasms / diagnostic imaging
  • Pituitary Neoplasms / drug therapy*
  • Pituitary Neoplasms / metabolism
  • Pituitary Neoplasms / pathology
  • Pituitary Neoplasms / surgery
  • Radiography
  • Somatostatin / analogs & derivatives*
  • Somatostatin / therapeutic use*
  • Treatment Outcome

Substances

  • Human Growth Hormone
  • Somatostatin